{"_id": "64fe80191544b4d920499d11", "pathologically confirmed pancreatic cancer": 1, "referred for image guided radiation therapy (IGRT)": 1, "age": 8, "able to consent": 3, "has Known coagulopathy/thrombocytopenia": 1, "is on antiplatelet/anticoagulant medication": 1, "cannot get off antiplatelet/anticoagulant medication 5-7 days prior to procedure": 1, "has gold allergy": 1, "has current infection": 1, "has EUS evidence of vessel interfering with path of fiducial marker": 1, "is pregnant": 1, "and": 8, "race": 1, "ethnicity": 1, "able to travel daily": 1, "has gastrointestinal (GI) conditions": 1, "number of days since taken antibiotics or probiotics": 1, "smokes/uses tobacco": 1, "consumes heavy alcohol": 1, "has major medical conditions": 1, "cancer type": 5, "has marker clip indicating location of target tumor in breast": 1, "tumor size": 2, "node status": 1, "candidate for breast-conserving surgery": 1, "able to tolerate prone body positioning during radiation therapy": 1, "prior ipsilateral-breast or thoracic radiotherapy": 1, "distance of target lesion from skin": 1, "estrogen receptor (ER) status": 1, "Her-2 amplification status": 1, "implanted hardware or other material": 1, "history of invasive malignancy": 1, "neoadjuvant chemotherapy prior to SABR or surgery": 1, "ECOG performance status": 3, "pregnancy test result": 1, "lymph node disease": 1, "candidate for breast conserving surgery": 1, "history of scleroderma or lupus erythematosus": 1, "distance of target tumor from skin": 1, "neoadjuvant chemotherapy": 1, "BRCA1 or BRCA2 gene mutation": 1, "pregnant or unwilling to undergo pregnancy screening": 1, "planning to initiate chemotherapy under the guidance of Moffitt": 1, "able to speak and read English": 1, "able to provide informed consent": 1, "psychiatric or neurological disorder": 1, "undergoing concurrent treatment for a second primary GI cancer": 1, "ECOG status": 2, "days since last chemotherapy for recurrent pancreatic cancer": 1, "use of parenteral or enteral nutrition": 1, "presence of malignant ascites": 1, "biopsiable lesion": 1, "previous treatment for ovarian cancer": 1, "life expectancy": 2, "organ and marrow function": 1, "eligible for neo-adjuvant chemotherapy": 1, "adequate contraception": 2, "active second malignancy": 1, "brain metastases": 1, "allergic reactions to carboplatin and paclitaxel": 1, "allergy to carboplatin, paclitaxel, or cremophor": 1, "uncontrolled concomitant illness": 1, "pregnant": 1, "HIV-positive patients receiving anti-retroviral therapy": 1, "or": 1, "diagnosis": 3, "stage": 1, "standard of care therapy exists": 1, "standard of care therapy is effective": 1, "ACT infusion prior to study enrollment": 1, "ACT type": 1, "prior ACT therapy completed": 1, "radiographic progression of residual disease": 1, "active disease observed on biopsy": 1, "measurable disease": 1, "longest diameter": 1, "disease suitable for assessment by pre- and post-biopsies": 1, "prior anti-programmed cell death (PD)-1 therapy": 1, "prior anti-PD-ligand (L)1 therapy": 1, "other immunotherapies": 1, "prior anti-PD-1 therapy": 1, "prior anti-PD-L1 therapy": 1, "ACT completed": 1, "residual disease documented": 1, "ACT related toxicities resolved to grade 1": 1, "alopecia": 1, "vitiligo": 1, "endocrine abnormalities requiring replacement therapy (grade 2)": 1, "prior other anti-cancer therapy for 28 days prior to atezolizumab administration": 1, "prior ACT therapy for 28 days prior to atezolizumab administration": 1, "absolute neutrophil count": 3, "platelets": 3, "hemoglobin": 3, "total bilirubin": 2, "aspartate aminotransferase (AST)": 1, "alanine aminotransferase (ALT)": 1, "AST": 2, "ALT": 2, "creatinine clearance": 2, "INR and aPTT": 1, "therapeutic anticoagulation": 1, "adequate contraception for women of child-bearing potential and men": 1, "pregnant women": 1, "ability to understand and willingness to sign a written informed consent document": 1, "chemotherapy or radiotherapy within 4 weeks prior to study entry": 1, "not recovered from adverse events due to agents administered more than 4 weeks earlier": 1, "hormone-replacement therapy or oral contraceptives": 1, "herbal therapy": 1, "palliative radiotherapy for bone metastases": 1, "prior treatment with anti-CTLA-4 antibody": 1, "history of severe immune-related adverse effects from anti-CTLA-4 antibody": 1, "treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1": 1, "treatment with systemic immunostimulatory agents within 6 weeks prior to cycle 1, day 1": 1, "treatment with systemic immunosuppressive medications within 2 weeks prior to cycle 1, day 1": 1, "acute, low dose, systemic immunosuppressant medications": 1, "inhaled corticosteroids and mineralocorticoids": 1, "low-dose supplemental corticosteroids for adrenocortical insufficiency": 1, "bisphosphonate therapy for symptomatic hypercalcemia": 1, "known primary central nervous system (CNS) malignancy": 1, "asymptomatic untreated CNS disease": 1, "asymptomatic treated CNS metastases": 1, "known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies": 1, "history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins": 1, "known clinically significant liver disease": 1, "past or resolved hepatitis B infection": 1, "hepatitis C virus (HCV) antibody negative or HCV RNA positive": 1, "history or risk of autoimmune disease": 2, "history of immune related events to anti-CTLA-4": 1, "controlled type 1 diabetes mellitus on a stable insulin regimen": 1, "eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only": 1, "history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan": 1, "active tuberculosis (TB)": 1, "RANKL inhibitor therapy": 1, "severe infections within 4 weeks prior to cycle 1, day 1": 1, "signs or symptoms of infection within 2 weeks prior to cycle 1, day 1": 1, "major surgical procedure within 28 days prior to cycle 1, day 1": 1, "administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1": 1, "uncontrolled intercurrent illness": 1, "previously tested positive for human immunodeficiency virus (HIV)": 1, "stable regimen of highly active anti-retroviral therapy (HAART)": 1, "requirement for concurrent antibiotics or antifungal agents": 1, "CD4 count above 250 cells/mcL": 1, "undetectable HIV viral load": 1, "histological diagnosis": 1, "distance from ampula": 1, "able to undergo imaging modalities": 1, "medical status for surgery and anesthesia": 1, "gender": 1, "pregnant or nursing": 1, "undergoing PET-CT or CT pancreatic protocol scan": 1, "female participant of child-bearing potential": 1, "agree to use birth control for 30 days following pimonidazole administration": 1, "kidney and liver function": 1, "able to provide informed consent and comply with study procedures": 1, "able to undergo MRI scans without pacemaker or metal": 1, "ECOG score": 1, "women who are pregnant or breastfeeding": 1, "contraindicated for MRI or gadolinium contrast agents": 1, "iodine contrast allergy": 1, "able to take standard pre-medications for CT scan": 1, "known active cancer with contraindicated prognosis for resection": 1, "depressed liver function": 1, "presence of any other co-existing condition increasing risk": 1, "renal cell patients with at least one prior VEGF TKI": 1, "ovarian cancer patients resistant to platinum therapy": 1, "colorectal cancer patients who have failed at least one oxaliplatin-containing regimen": 1, "number of prior therapies for metastatic disease": 1, "estimated life expectancy": 1, "leukocytes": 2, "serum total bilirubin": 1, "AST/ALT": 1, "serum creatinine": 1, "INR/PT": 1, "aPTT": 1, "UPCR": 1, "archival tissue available": 1, "measurable disease based on RECIST 1.1": 1, "negative pregnancy test": 2, "willingness to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication for female patients of childbearing potential": 1, "ability to understand and the willingness to sign a written informed consent document": 1, "dose expansion part 2 PD-1/PD-L1 resistant or refractory melanoma and renal cell cancer only: subjects must have received prior immunotherapy with an anti-PD-1 or anti-PD-L1 containing regimen and must have progressive or recurrent disease after prior PD-1/PD-L1 directed therapy; primary resistance is determined at the time of initial restaging from initiation of treatment, as evidenced by progression by RECIST 1.1; acquired resistance would be a subject who had a best overall RECIST response of stable disease, partial response, or complete response confirmed radiographically by a second scan who subsequently developed progressive disease by RECIST 1.1 at any time thereafter": 1, "dose expansion part 2 sarcoma only: subjects must have received standard of care treatment": 1, "days since chemotherapy, targeted small molecule therapy, or radiotherapy": 1, "days since post-operative after major surgery": 1, "days since participating in or have participated in a study of an investigational agent or using an investigational device": 1, "days since diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy": 1, "days since prior monoclonal antibody": 1, "known additional malignancy that is progressing or requires active treatment": 1, "lesions suspected to be at higher-risk for bleeding such as bowel involvement with tumor that invades into the bowel wall or involves the intraluminal component of bowel by imaging or direct visualization or central pulmonary lesions": 1, "ulcerated skin lesions": 1, "full anti-coagulant therapy Coumadin": 1, "poorly-controlled hypertension": 1, "pregnant or nursing women": 1, "known brain metastases": 1, "carcinomatous meningitis": 1, "previously treated brain metastases who are not stable, have evidence of new or enlarging brain metastases, or are using steroids for at least 7 days prior to trial treatment": 1, "history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-3475 and ziv-aflibercept": 1, "active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents": 1, "history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator": 1, "known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial": 1, "received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or ziv-aflibercept": 1, "uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements": 1, "pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment": 1, "human immunodeficiency virus (HIV) positive and do not meet the eligibility requirements": 1, "known active hepatitis B or hepatitis C": 1, "received a live vaccine within 30 days prior to the first dose of trial treatment": 1, "history within 6 months prior to treatment of myocardial infarction, severe/unstable angina pectoris, coronary artery bypass graft (CABG), New York Heart Association (NYHA) class III or IV congestive heart failure (CHF), stroke or transient ischemic attack (TIA)": 1, "history within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event": 1, "molecular diagnosis": 1, "genetic abnormalities": 1, "tumor recurrence": 1, "tumor progression": 1, "distance from critical structures": 1, "surgical cohort": 1, "MGMT methylation status available": 1, "time since previous treatments": 1, "time since previous radiation": 1, "time since previous temozolomide": 1, "time since previous investigational agents": 1, "Karnofsky performance status": 1, "history and physical examination": 1, "absolute lymphocyte count": 1, "alkaline phosphatase": 1, "contraception": 1, "HIV positive": 1, "undetectable viral load": 1, "stable HAART regimen": 1, "no concurrent antibiotics or antifungal agents": 1, "HBV viral load undetectable": 1, "HBV positive": 1, "immune to hepatitis B": 1, "HCV treated and cured": 1, "HCV viral load undetectable": 1, "HCV positive": 1, "informed consent": 1, "prior radiotherapy treatment plan details available": 1, "IDH1 or IDH2 mutation": 1, "germline DNA repair defect": 1, "diffuse leptomeningeal disease": 1, "contrast-enhancing tumor in brainstem or spinal cord": 1, "mass effect or midline shift": 1, "prior bevacizumab therapy": 1, "prior or concurrent malignancy": 1, "prior bone marrow or solid organ transplantation": 1, "prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents": 1, "systemic immunostimulatory agents within 4 weeks": 1, "systemic immunosuppressive medications within 2 weeks": 1, "systemic corticosteroids > 2 mg of dexamethasone daily within 5 days": 1, "increased risk for gastrointestinal perforations": 1, "hypersensitivity to Chinese hamster ovary cell products or recombinant human antibodies": 1, "severe allergic or hypersensitivity reactions to antibodies or fusion proteins": 1, "clinically significant liver disease": 1}